logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12115179 B1

PDFFull Text
Date of Patent:
Oct. 15, 2024

Filed:

May. 19, 2023

Pharmaceutical composition, methods for treating and uses thereof

Applicant:

Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, DE;

Inventors:

Peter Eickelmann, Mittelbiberach, DE;

Michael Mark, Biberach an der Riss, DE;

Leo John Seman, Cheshire, CT (US);

Leo Thomas, Biberach an der Riss, DE;

Uli Christian Broedl, Oakville, CA;

Rolf Grempler, Mittelbiberach, DE;

Assignee:

Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE;

Attorney:

David L. Kersher

Primary Examiner:

Traviss C McIntosh, III

Int. Cl.
CPC ...
A61K 31/7048 (2006.01); A61K 31/00 (2006.01); A61K 31/155 (2006.01); A61K 31/198 (2006.01); A61K 31/341 (2006.01); A61K 31/351 (2006.01); A61K 31/39 (2006.01); A61K 31/403 (2006.01); A61K 31/4439 (2006.01); A61K 31/522 (2006.01); A61K 31/70 (2006.01); A61K 31/7004 (2006.01); A61K 31/7008 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A61K 31/00 (2013.01); A61K 31/155 (2013.01); A61K 31/198 (2013.01); A61K 31/341 (2013.01); A61K 31/351 (2013.01); A61K 31/39 (2013.01); A61K 31/403 (2013.01); A61K 31/4439 (2013.01); A61K 31/522 (2013.01); A61K 31/70 (2013.01); A61K 31/7004 (2013.01); A61K 31/7008 (2013.01); A61K 45/06 (2013.01);
Abstract

The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Find Patent Forward Citations

Loading…